Insider Selling: Clearmind Medicine (NASDAQ:CMND) Major Shareholder Sells $73,280.09 in Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt sold 22,139 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total transaction of $73,280.09. Following the completion of the sale, the insider owned 81,353 shares in the company, valued at approximately $269,278.43. This trade represents a 21.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, June 15th, Financial Lp Hrt sold 3,183 shares of Clearmind Medicine stock. The shares were sold at an average price of $3.32, for a total transaction of $10,567.56.
• On Friday, June 12th, Financial Lp Hrt sold 2,102 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.36, for a total value of $7,062.72.
• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The shares were sold at an average price of $0.12, for a total value of $27,022.92.
• On Wednesday, June 10th, Financial Lp Hrt acquired 2,159,052 shares of Clearmind Medicine stock. The stock was bought at an average cost of $0.15 per share, with a total value of $323,857.80.

Clearmind Medicine Stock Performance

NASDAQ CMND opened at $3.07 on Friday. The business’s 50 day moving average price is $5.36 and its 200-day moving average price is $14.74. Clearmind Medicine Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $524.00. The company has a market cap of $3.13 million, a P/E ratio of -0.02 and a beta of 0.64.

Clearmind Medicine (NASDAQ:CMND) last posted its quarterly earnings data on Monday, June 15th. The company reported ($6.78) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Clearmind Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.